Indication

Primary hyperoxaluria type I

Primary hyperoxaluria type I is a rare autosomal recessive metabolic disorder caused by pathogenic variants in the *AGXT* gene, leading to a deficiency of the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase. Read more about Primary hyperoxaluria type I

3 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Primary hyperoxaluria type I therapies.

Showing 1–3 of 3 drugs

Filter & compare in the drug finder →Opens the drug finder with Primary hyperoxaluria type I preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Primary hyperoxaluria type I.

Primary hyperoxaluria type I is a rare autosomal recessive metabolic disorder caused by pathogenic variants in the *AGXT* gene, leading to a deficiency of the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase.

This enzymatic defect causes an overproduction of endogenous oxalate, which is primarily excreted by the kidneys as insoluble calcium oxalate.

The condition primarily impacts the renal system across pediatric and adult populations, characteristically manifesting as recurrent nephrolithiasis and progressive nephrocalcinosis.

As renal filtration declines, progressive hyperoxalemia can precipitate systemic oxalosis, resulting in extrarenal calcium oxalate deposition throughout the skeleton, myocardium, eyes, and vasculature.

Personalize your experience

Follow Primary hyperoxaluria type I and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it